Skip to main content
Top
Published in: Clinical and Translational Oncology 10/2015

01-10-2015 | Research Article

A retrospective analysis of lung metastasis in 64 patients with alveolar soft part sarcoma

Authors: Y.-P. Liu, J. Jin, W.-H. Wang, S.-L. Wang, Y.-W. Song, H. Fang, H. Ren, X.-F. Liu, Z.-H. Yu, Y.-X. Li

Published in: Clinical and Translational Oncology | Issue 10/2015

Login to get access

Abstract

Objectives

To analyse the lung metastasis and possible factors influencing lung metastasis in alveolar soft part sarcoma (ASPS) patients.

Methods

The medical records of 64 consecutive ASPS patients were reviewed to analyse their treatments, features of lung metastasis, and possible factors influencing lung metastasis.

Results

Thirty-six females and 28 males with a median age of 27 years were included. The primary disease sites were the extremities in 51 patients and other locations in 13 patients. The median primary tumour size was 5 cm. Wide local excision of the primary tumour was performed on 56 patients (87.5 %). Thirteen patients (20.3 %) received postoperative adjuvant radiotherapy, and nine patients (14.1 %) underwent adjuvant chemotherapy. Twelve patients (18.8 %) presented with metastatic lung disease. Twenty-nine patients (45.3 %) developed metastatic lung disease during follow-up. Lung metastasis occurred in 64.1 % of the patients. Lung metastasis was detected at a median interval of 20 months after primary ASPS diagnosis. Being male, >20 years of age, having a primary tumour size ≥5 cm, and local recurrence were associated with a greater rate of lung metastasis. Median survival after the diagnosis of lung metastasis was 34 months. The 5-year survival rates were 64.1 and 95.2 % for patients with and without lung metastasis (P < 0.001). Thirty-seven patients with metastatic lung disease received anthracycline- and ifosfamide-based chemotherapy. One patient experienced a partial remission.

Conclusions

ASPS patients have a high prevalence of lung metastasis. Sex, age, primary tumour size, and local recurrence are major factors influencing lung metastasis. Chemotherapy is not efficacious in ASPS patients with lung metastasis.
Literature
1.
go back to reference Anderson ME, Hornicek FJ, Gebhardet MC, Raskin KA. Alveolar soft part sarcoma: a rare and enigmatic entity. Clin Orthop Relat Res. 2005;438:144–8.CrossRefPubMed Anderson ME, Hornicek FJ, Gebhardet MC, Raskin KA. Alveolar soft part sarcoma: a rare and enigmatic entity. Clin Orthop Relat Res. 2005;438:144–8.CrossRefPubMed
2.
go back to reference Enzinger FM, Weiss SW. Malignant tumors of uncertain type. In: Enzinger FM, Weiss SW, editors. Soft tissue tumors. 3rd ed. St. Louis: Mosby; 1995. p. 1067–74. Enzinger FM, Weiss SW. Malignant tumors of uncertain type. In: Enzinger FM, Weiss SW, editors. Soft tissue tumors. 3rd ed. St. Louis: Mosby; 1995. p. 1067–74.
4.
5.
go back to reference Rekhi B, Ingle A, Agarwal M, Puri A, Laskar S, Jambhekar NA. Alveolar soft part sarcoma ‘revisited’: clinicopathological review of 47 cases from a tertiary cancer referral centre, including immunohistochemical expression of TFE3 in 22 cases and 21 other tumours. Pathology. 2012;44:11–7.CrossRefPubMed Rekhi B, Ingle A, Agarwal M, Puri A, Laskar S, Jambhekar NA. Alveolar soft part sarcoma ‘revisited’: clinicopathological review of 47 cases from a tertiary cancer referral centre, including immunohistochemical expression of TFE3 in 22 cases and 21 other tumours. Pathology. 2012;44:11–7.CrossRefPubMed
6.
go back to reference Zarrin-Khameh N, Kaye KS. Alveolar Soft Part Sarcoma. Arch Pathol Lab Med. 2007;131:488–91.PubMed Zarrin-Khameh N, Kaye KS. Alveolar Soft Part Sarcoma. Arch Pathol Lab Med. 2007;131:488–91.PubMed
7.
go back to reference Pang LJ, Chang B, Zou H, Qi Y, Jiang JF, Li HA, et al. Alveolar soft part sarcoma: a bimarker diagnostic strategy using TFE3 immunoassay and ASPL-TFE3 fusion transcripts in paraffin-embedded tumor tissues. Diagn Mol Pathol. 2008;17:245–52.CrossRefPubMed Pang LJ, Chang B, Zou H, Qi Y, Jiang JF, Li HA, et al. Alveolar soft part sarcoma: a bimarker diagnostic strategy using TFE3 immunoassay and ASPL-TFE3 fusion transcripts in paraffin-embedded tumor tissues. Diagn Mol Pathol. 2008;17:245–52.CrossRefPubMed
8.
go back to reference Williams A, Bartle G, Sumathi VP, Meis JM, Mangham DC, Grimer RJ, et al. Detection of ASPL/TFE3 fusion transcripts and the TFE3 antigen in formalin-fixed, paraffin-embedded tissue in a series of 18 cases of alveolar soft part sarcoma: useful diagnostic tools in cases with unusual histological features. Virchows Arch. 2011;458:291–300.CrossRefPubMed Williams A, Bartle G, Sumathi VP, Meis JM, Mangham DC, Grimer RJ, et al. Detection of ASPL/TFE3 fusion transcripts and the TFE3 antigen in formalin-fixed, paraffin-embedded tissue in a series of 18 cases of alveolar soft part sarcoma: useful diagnostic tools in cases with unusual histological features. Virchows Arch. 2011;458:291–300.CrossRefPubMed
9.
10.
go back to reference Orbach D, Brennan B, Casanova M, Bergeron C, Mosseri V, Francotte N, et al. Paediatric and adolescent alveolar soft part sarcoma: a joint series from European cooperative groups. Pediatric Blood Cancer. 2013;60:1826–32.CrossRefPubMed Orbach D, Brennan B, Casanova M, Bergeron C, Mosseri V, Francotte N, et al. Paediatric and adolescent alveolar soft part sarcoma: a joint series from European cooperative groups. Pediatric Blood Cancer. 2013;60:1826–32.CrossRefPubMed
11.
go back to reference Hilbert M, Mary P, Larroquet M, Serinet MO, Helfre S, Brisse H, et al. Alveolar soft part sarcoma in childhood: is Sunitinib-Sutent(R) treatment an effective approach? Pediatric Blood Cancer. 2012;58:475–6.CrossRefPubMed Hilbert M, Mary P, Larroquet M, Serinet MO, Helfre S, Brisse H, et al. Alveolar soft part sarcoma in childhood: is Sunitinib-Sutent(R) treatment an effective approach? Pediatric Blood Cancer. 2012;58:475–6.CrossRefPubMed
12.
go back to reference Christopherson WM, Foote FW, Stewart FW. Alveolar soft-part sarcomas: structurally characteristic tumors of uncertain histogenesis. Cancer. 1952;5:100–11.CrossRefPubMed Christopherson WM, Foote FW, Stewart FW. Alveolar soft-part sarcomas: structurally characteristic tumors of uncertain histogenesis. Cancer. 1952;5:100–11.CrossRefPubMed
13.
go back to reference Daigeler A, Kuhnen C, Hauser J, Goertz O, Tilkorn D, Steinstraesser L, et al. Alveolar soft part sarcoma: clinicopathological findings in a series of 11 cases. World J Surg Oncol. 2008;6:71–8.CrossRefPubMedPubMedCentral Daigeler A, Kuhnen C, Hauser J, Goertz O, Tilkorn D, Steinstraesser L, et al. Alveolar soft part sarcoma: clinicopathological findings in a series of 11 cases. World J Surg Oncol. 2008;6:71–8.CrossRefPubMedPubMedCentral
14.
go back to reference Lieberman PH, Brennan MF, Kimmel M, Erlandson RA, Garin-Chesa P, Flehinger BY. Alveolar soft-part sarcoma: a clinico-pathologic study of half a century. Cancer. 1989;63:1–13.CrossRefPubMed Lieberman PH, Brennan MF, Kimmel M, Erlandson RA, Garin-Chesa P, Flehinger BY. Alveolar soft-part sarcoma: a clinico-pathologic study of half a century. Cancer. 1989;63:1–13.CrossRefPubMed
15.
go back to reference Reichardt P, Lindner T, Pink D, Thuss-Patience PC, Kretzschmar A, Dorken B. Chemotherapy in alveolar soft part sarcomas: what do we know? European J Cancer. 2003;39:1511–6.CrossRef Reichardt P, Lindner T, Pink D, Thuss-Patience PC, Kretzschmar A, Dorken B. Chemotherapy in alveolar soft part sarcomas: what do we know? European J Cancer. 2003;39:1511–6.CrossRef
16.
go back to reference Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.CrossRefPubMed Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.CrossRefPubMed
17.
go back to reference Sood S, Baheti AD, Shinagare AB, Jagannathan JP, Hornick JL, Ramaiya NH, et al. Imaging features of primary and metastatic alveolar soft part sarcoma: single institute experience in 25 patients. British J Radiol. 2014. doi:10.1259/bjr.20130719. Sood S, Baheti AD, Shinagare AB, Jagannathan JP, Hornick JL, Ramaiya NH, et al. Imaging features of primary and metastatic alveolar soft part sarcoma: single institute experience in 25 patients. British J Radiol. 2014. doi:10.​1259/​bjr.​20130719.
18.
go back to reference Lorigan JG, O’Keeffe FN, Evans HL, Wallace S. The radiologic manifestations of alveolar soft-part sarcoma. Am J Roentgenol. 1989;153:335–9.CrossRef Lorigan JG, O’Keeffe FN, Evans HL, Wallace S. The radiologic manifestations of alveolar soft-part sarcoma. Am J Roentgenol. 1989;153:335–9.CrossRef
19.
go back to reference Portera CA, Ho V, Patel SR, Hunt KK, Feig BW, Respondek PM, et al. Alveolar soft part sarcoma: clinical course and patterns of metastasis in 70 patients treated at a single institution. Cancer. 2001;91:585–91.CrossRefPubMed Portera CA, Ho V, Patel SR, Hunt KK, Feig BW, Respondek PM, et al. Alveolar soft part sarcoma: clinical course and patterns of metastasis in 70 patients treated at a single institution. Cancer. 2001;91:585–91.CrossRefPubMed
20.
go back to reference Kayton ML, Meyers P, Wexler LH, Gerald WL, Laquaglia MP. Clinical presentation, treatment, and outcome of alveolar soft part sarcoma in children, adolescents, and young adults. J Pediatr Surg. 2006;41:187–93.CrossRefPubMed Kayton ML, Meyers P, Wexler LH, Gerald WL, Laquaglia MP. Clinical presentation, treatment, and outcome of alveolar soft part sarcoma in children, adolescents, and young adults. J Pediatr Surg. 2006;41:187–93.CrossRefPubMed
21.
go back to reference Cho YJ, Kim JY. Alveolar soft part sarcoma: clinical presentation, treatment and outcome in a series of 19 patients. Clin Orthopedic Surg. 2014;6:80–6.CrossRef Cho YJ, Kim JY. Alveolar soft part sarcoma: clinical presentation, treatment and outcome in a series of 19 patients. Clin Orthopedic Surg. 2014;6:80–6.CrossRef
22.
go back to reference Falkenstern-Ge RF, Kimmich M, Wohlleber M, Grabner A, Friedel G, Ott G, et al. Lung metastasis of primary alveolar soft-part sarcoma occurring 20 years after initial treatment. Case Rep Oncolog Med. 2013. doi:10.1155/2013/690520. Falkenstern-Ge RF, Kimmich M, Wohlleber M, Grabner A, Friedel G, Ott G, et al. Lung metastasis of primary alveolar soft-part sarcoma occurring 20 years after initial treatment. Case Rep Oncolog Med. 2013. doi:10.​1155/​2013/​690520.
23.
go back to reference Lillehei KO, Kleinschmidt-DeMasters B, Mitchell DH, Spector E, Kruse CA. Alveolar soft part sarcoma: an unusually long interval between presentation and brain metastasis. Human Pathol. 1993;24:1030–4.CrossRef Lillehei KO, Kleinschmidt-DeMasters B, Mitchell DH, Spector E, Kruse CA. Alveolar soft part sarcoma: an unusually long interval between presentation and brain metastasis. Human Pathol. 1993;24:1030–4.CrossRef
24.
go back to reference Casanova M, Ferrari A, Bisogno G, Cecchetto G, Basso E, Bernardi BD, et al. Alveolar soft part sarcoma in children and adolescents: a report from the Soft-Tissue Sarcoma Italian Cooperative Group. Ann Oncol. 2000;11:1445–9.CrossRefPubMed Casanova M, Ferrari A, Bisogno G, Cecchetto G, Basso E, Bernardi BD, et al. Alveolar soft part sarcoma in children and adolescents: a report from the Soft-Tissue Sarcoma Italian Cooperative Group. Ann Oncol. 2000;11:1445–9.CrossRefPubMed
25.
go back to reference Ogose A, Yazawa Y, Ueda T, Hotta T, Kawashima H, Hatano H, et al. Alveolar soft part sarcoma in japan: multi-institutional study of 57 patients from the Japanese Musculoskeletal Oncology Group. Oncology. 2003;65:7–13.CrossRefPubMed Ogose A, Yazawa Y, Ueda T, Hotta T, Kawashima H, Hatano H, et al. Alveolar soft part sarcoma in japan: multi-institutional study of 57 patients from the Japanese Musculoskeletal Oncology Group. Oncology. 2003;65:7–13.CrossRefPubMed
27.
go back to reference Pennacchioli E, Fiore M, Collini P, Radaelli S, Dileo P, Stacchiotti S, et al. Alveolar soft part sarcoma: clinical presentation, treatment, and outcome in a 33 patients at a single institution. Ann Surg Oncol. 2010;7:3229–33.CrossRef Pennacchioli E, Fiore M, Collini P, Radaelli S, Dileo P, Stacchiotti S, et al. Alveolar soft part sarcoma: clinical presentation, treatment, and outcome in a 33 patients at a single institution. Ann Surg Oncol. 2010;7:3229–33.CrossRef
28.
go back to reference Evans HL. Alveolar soft-part sarcoma. A study of 13 typical examples and one with a histologically atypical component. Cancer. 1985;55:912–7.CrossRefPubMed Evans HL. Alveolar soft-part sarcoma. A study of 13 typical examples and one with a histologically atypical component. Cancer. 1985;55:912–7.CrossRefPubMed
29.
go back to reference Ferguson PC, Deheshi BM, Chung P, Catton CN, O’Sullivan B, Gupta A, et al. Soft tissue sarcoma presenting with metastatic disease: outcome with primary surgical resection. Cancer. 2011;117:372–9.CrossRefPubMed Ferguson PC, Deheshi BM, Chung P, Catton CN, O’Sullivan B, Gupta A, et al. Soft tissue sarcoma presenting with metastatic disease: outcome with primary surgical resection. Cancer. 2011;117:372–9.CrossRefPubMed
30.
go back to reference Kane JM, Finley JW, Driscoll D, Kraybill WG, Gibbs JF. The treatment and outcome of patients with soft tissue sarcomas and synchronous metastases. Sarcoma. 2002;6:69–73.CrossRefPubMedPubMedCentral Kane JM, Finley JW, Driscoll D, Kraybill WG, Gibbs JF. The treatment and outcome of patients with soft tissue sarcomas and synchronous metastases. Sarcoma. 2002;6:69–73.CrossRefPubMedPubMedCentral
31.
go back to reference van Ruth S, van Coevorden F, Peterse JL, Kroon BB. Alveolar soft part sarcoma: a report of 15 cases. Eur J Cancer. 2002;38:1324–8.CrossRefPubMed van Ruth S, van Coevorden F, Peterse JL, Kroon BB. Alveolar soft part sarcoma: a report of 15 cases. Eur J Cancer. 2002;38:1324–8.CrossRefPubMed
Metadata
Title
A retrospective analysis of lung metastasis in 64 patients with alveolar soft part sarcoma
Authors
Y.-P. Liu
J. Jin
W.-H. Wang
S.-L. Wang
Y.-W. Song
H. Fang
H. Ren
X.-F. Liu
Z.-H. Yu
Y.-X. Li
Publication date
01-10-2015
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 10/2015
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-015-1308-9

Other articles of this Issue 10/2015

Clinical and Translational Oncology 10/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine